Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151502 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
A Phase 3 study of Alzheimers Disease, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT00151502: Completed Phase 3 study of Alzheimers Disease, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00151502 is a Phase 3 study of Alzheimers Disease that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 600 participants, below the 3,922-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00151502, a Phase 3 study of Alzheimers Disease, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Atorvastatin
Study Locations (20)
Florida
- Pfizer Investigational Site - Fort Lauderdale
- Pfizer Investigational Site - Fort Myers
- Pfizer Investigational Site - Miami Beach
- Pfizer Investigational Site - Pompano Beach
- Pfizer Investigational Site - St. Petersburg
- Pfizer Investigational Site - West Palm Beach
California
- Pfizer Investigational Site - Fresno
- Pfizer Investigational Site - Laguna Hills
- Pfizer Investigational Site - San Francisco
Massachusetts
- Pfizer Investigational Site - South Dartmouth
- Pfizer Investigational Site - West Yarmouth
- Pfizer Investigational Site - Worcester
New Jersey
- Pfizer Investigational Site - Jamesburg
- Pfizer Investigational Site - Princeton
Arizona
- Pfizer Investigational Site - Sun City
Indiana
- Pfizer Investigational Site - Fort Wayne
Kentucky
- Pfizer Investigational Site - Paducah
Louisiana
- Pfizer Investigational Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2002-11 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
What the finished NCT00151502 record still lists
NCT00151502 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 3,922-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00151502 names 20 study sites across 10 states, led by Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00151502 about?
NCT00151502 is a clinical study titled "To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.". The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.
What is the current status of trial NCT00151502?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2002-11. Estimated completion is 2007-07.
What conditions does trial NCT00151502 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00151502?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00151502?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00151502 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00151502's enrollment target sits among peer trials
600 24th of 147 higher than 123 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia